Education
About Us
Working with TipRanks
Follow Us
Edesa Biotech (EDSA)
:EDSA
EDSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.55 - $5.59
Previous CloseN/A
Volume1.31K
Average Volume (3M)17.46K
Market Cap
$16.15M
Enterprise Value$13.43M
Total Cash (Recent Filing)$4.27M
Total Debt (Recent Filing)$78.31K
Price to Earnings (P/E)―
Beta0.60
Next Earnings
May 09, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding7,022,678
10 Day Avg. Volume7,434
30 Day Avg. Volume17,465
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.27
Forecast
1Y Price Target
$21.00Price Target Upside813.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Edesa Biotech News
PremiumCompany Announcements
Edesa Biotech Appoints New CFO Amid Leadership Change
PremiumCompany Announcements
Edesa Biotech Advances Vitiligo Treatment Amidst Solid Financial Backing
PremiumCompany Announcements
Edesa Biotech Secures $15 Million for CXCL10 Antibody Program---
Ownership Overview
15.22% Insiders
0.62% Mutual Funds
1.57% Other Institutional Investors
82.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $1.55 and its highest was $5.59 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $16.15M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is May 09, 2025 which is in 15 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on Feb 14, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.17.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Undervalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.4.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 7,022,678 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went down -7.063%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
---
Company Description
Edesa Biotech
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
---
EDSA Stock 12 Month Forecast
Average Price Target
$21.00
▲(813.04% Upside)
Technical Analysis
Palatin Technologies
―
Accelerate Diagnostics
―
Lipocine
―
Nephros
―
Inspira Technologies Oxy BHN
―
Best Analysts Covering EDSA
1 Year
1 Year Success Rate
0/17 ratings generated profit
1 Year Average Return
-46.42%
reiterated a buy rating last month
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.42% per trade.
---